ABP-671

DRUG6 trials

Sponsors

Atom Therapeutics Co., Ltd

Conditions

Food-drug InteractionGoutHyperuricemia

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

CompletedNCT03906006

Atom Therapeutics Co., LtdGout, Hyperuricemia

Start: 2018-10-17End: 2019-06-20Updated: 2020-07-29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

CompletedNCT04060173

Atom Therapeutics Co., LtdGout, Hyperuricemia

Start: 2019-09-05End: 2020-02-07Updated: 2020-02-12

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

CompletedNCT04303039

Atom Therapeutics Co., LtdFood-drug Interaction, Gout

Start: 2020-05-22End: 2020-06-19Updated: 2020-06-23

Phase 2

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia

CompletedNCT04638543

Atom Therapeutics Co., LtdGout, Hyperuricemia

Start: 2020-11-27End: 2021-10-26Updated: 2023-04-12

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

CompletedNCT05818085

Atom Therapeutics Co., LtdGout

Start: 2023-08-11End: 2025-03-30Updated: 2025-12-22

Extension Study of ABP-671 in Participants With Gout

TerminatedNCT06276556

Atom Therapeutics Co., LtdGout

Start: 2024-04-22End: 2024-09-05Updated: 2025-07-16